Medlive Technology Co., Ltd.

SEHK:2192 Voorraadrapport

Marktkapitalisatie: HK$6.8b

Medlive Technology Toekomstige groei

Future criteriumcontroles 2/6

Medlive Technology zal naar verwachting groeien in winst en omzet met respectievelijk 7.7% en 16.2% per jaar. De winst per aandeel zal naar verwachting groeien met 6.1% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 5.9% zijn.

Belangrijke informatie

7.7%

Groei van de winst

6.1%

Groei van de winst per aandeel

Healthcare Services winstgroei31.0%
Inkomstengroei16.2%
Toekomstig rendement op eigen vermogen5.9%
Dekking van analisten

Low

Laatst bijgewerkt29 Aug 2024

Recente toekomstige groei-updates

Results: Medlive Technology Co., Ltd. Exceeded Expectations And The Consensus Has Updated Its Estimates

Mar 26
Results: Medlive Technology Co., Ltd. Exceeded Expectations And The Consensus Has Updated Its Estimates

Recent updates

Investors Shouldn't Be Too Comfortable With Medlive Technology's (HKG:2192) Earnings

Oct 02
Investors Shouldn't Be Too Comfortable With Medlive Technology's (HKG:2192) Earnings

Pinning Down Medlive Technology Co., Ltd.'s (HKG:2192) P/E Is Difficult Right Now

Sep 27
Pinning Down Medlive Technology Co., Ltd.'s (HKG:2192) P/E Is Difficult Right Now

Medlive Technology (HKG:2192) Could Be Struggling To Allocate Capital

Jul 04
Medlive Technology (HKG:2192) Could Be Struggling To Allocate Capital

Medlive Technology Co., Ltd.'s (HKG:2192) Business Is Yet to Catch Up With Its Share Price

Apr 08
Medlive Technology Co., Ltd.'s (HKG:2192) Business Is Yet to Catch Up With Its Share Price

Medlive Technology (HKG:2192) Is Reinvesting At Lower Rates Of Return

Feb 20
Medlive Technology (HKG:2192) Is Reinvesting At Lower Rates Of Return

Are Medlive Technology Co., Ltd. (HKG:2192) Investors Paying Above The Intrinsic Value?

Jan 10
Are Medlive Technology Co., Ltd. (HKG:2192) Investors Paying Above The Intrinsic Value?

Medlive Technology Co., Ltd.'s (HKG:2192) Intrinsic Value Is Potentially 20% Below Its Share Price

Sep 27
Medlive Technology Co., Ltd.'s (HKG:2192) Intrinsic Value Is Potentially 20% Below Its Share Price

Medlive Technology (HKG:2192) Is Reinvesting At Lower Rates Of Return

Jul 10
Medlive Technology (HKG:2192) Is Reinvesting At Lower Rates Of Return

Medlive Technology Co., Ltd. (HKG:2192) Shares Slammed 28% But Getting In Cheap Might Be Difficult Regardless

May 11
Medlive Technology Co., Ltd. (HKG:2192) Shares Slammed 28% But Getting In Cheap Might Be Difficult Regardless

Robust Earnings May Not Tell The Whole Story For Medlive Technology (HKG:2192)

May 02
Robust Earnings May Not Tell The Whole Story For Medlive Technology (HKG:2192)

Results: Medlive Technology Co., Ltd. Exceeded Expectations And The Consensus Has Updated Its Estimates

Mar 26
Results: Medlive Technology Co., Ltd. Exceeded Expectations And The Consensus Has Updated Its Estimates

Here's What's Concerning About Medlive Technology's (HKG:2192) Returns On Capital

Feb 06
Here's What's Concerning About Medlive Technology's (HKG:2192) Returns On Capital

There Are Reasons To Feel Uneasy About Medlive Technology's (HKG:2192) Returns On Capital

Oct 31
There Are Reasons To Feel Uneasy About Medlive Technology's (HKG:2192) Returns On Capital

Medlive Technology (HKG:2192) Could Be Struggling To Allocate Capital

Jul 14
Medlive Technology (HKG:2192) Could Be Struggling To Allocate Capital

These Analysts Just Made A Massive Downgrade To Their Medlive Technology Co., Ltd. (HKG:2192) EPS Forecasts

Apr 03
These Analysts Just Made A Massive Downgrade To Their Medlive Technology Co., Ltd. (HKG:2192) EPS Forecasts

Is Medlive Technology Co., Ltd. (HKG:2192) Worth HK$9.5 Based On Its Intrinsic Value?

Feb 22
Is Medlive Technology Co., Ltd. (HKG:2192) Worth HK$9.5 Based On Its Intrinsic Value?

Winst- en omzetgroeiprognoses

SEHK:2192 - Toekomstschattingen van analisten en financiële gegevens uit het verleden (CNY Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
12/31/2026834363N/A2303
12/31/2025689317N/A1683
12/31/2024537274N/A1113
6/30/20244822905792N/A
3/31/20244472666397N/A
12/31/202341224269102N/A
9/30/20233842166990N/A
6/30/20233561896979N/A
3/31/20233351536978N/A
12/31/20223141177077N/A
9/30/2022300835157N/A
6/30/2022286483236N/A
3/31/2022285443740N/A
12/31/2021284414244N/A
9/30/2021270557173N/A
6/30/202125570100101N/A
3/31/202123478105106N/A
12/31/202021485110111N/A
12/31/2019122312628N/A
12/31/201883141922N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei 2192 ( 7.7% per jaar) ligt boven de spaarquote ( 2.3% ).

Winst versus markt: De winst van 2192 ( 7.7% per jaar) zal naar verwachting langzamer groeien dan de markt Hong Kong ( 11.6% per jaar).

Hoge groeiwinsten: De winst van 2192 zal naar verwachting groeien, maar niet aanzienlijk.

Omzet versus markt: De omzet van 2192 ( 16.2% per jaar) zal naar verwachting sneller groeien dan de markt Hong Kong ( 7.8% per jaar).

Hoge groei-inkomsten: De omzet van 2192 ( 16.2% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.


Groeiprognoses winst per aandeel


Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen 2192 zal naar verwachting over 3 jaar laag zijn ( 5.9 %).


Ontdek groeibedrijven